Atacicept: A new B lymphocyte-targeted therapy for multiple sclerosis;Atacicept bei Multipler Sklerose : Ein neuer B-Lymphozyten-gerichteter Therapieansatz

Nervenarzt

Volumn 80, Issue 12, 2009, Pages 1462-1472

  Hartung, H P ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Atacicept; B cell targeted therapy; B lymphocytes; Multiple sclerosis

Indexed keywords

APRIL PROTEIN; ATACICEPT;

ANIMAL MODEL; B LYMPHOCYTE; CELL FUNCTION; CELL LINEAGE; CELL MATURATION; CELL SURVIVAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOPATHOLOGY; MEMORY CELL; MULTIPLE SCLEROSIS; NONHUMAN; PRE B LYMPHOCYTE; PROTEIN ANALYSIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; EVIDENCE-BASED MEDICINE; HUMANS; MULTIPLE SCLEROSIS; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 73949150766     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-009-2838-6     Document Type: Review

References (86)

1. Lassmann H, Bruck W, Lucchinetti CF (2007) The immunopathology of multiple sclerosis: an overview. Brain Pathol 17:210-218
2. Kornek B et al (2000) Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 157:267-276
3. Lucchinetti C et al (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47:707-717
4. Marrie RA (2004) Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol 3:709-718
5. Hohlfeld R, Wekerle H (2004) Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci U S A 101 [Suppl 2]:14599-14606
6. Willer CJ, Dyment DA, Risch NJ et al (2003) Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci U S A 100:12877-12882
7. Barcellos LF et al (2003) HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 72:710-716
8. Poser CM (2006) The multiple sclerosis trait and the development of multiple sclerosis: genetic vulnerability and environmental effect. Clin Neurol Neurosurg 108:227-233
9. Sospedra M, Martin R (2005) Immunology of multiple sclerosis. Annu Rev Immunol 23:683-747
10. Chitnis T (2007) The role of CD4 T cells in the pathogenesis of multiple sclerosis. Int Rev Neurobiol 79:43-72
11. Hemmer B, Nessler S, Zhou D et al (2006) Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol 2:201-211
12. Delgado S, Sheremata WA (2006) The role of CD4+ T-cells in the development of MS. Neurol Res 28:245-249
13. Hemmer B, Archelos JJ, Hartung HP (2002) New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 3:291-301
14. Medana I, Martinic MA, Wekerle H, Neumann H (2001) Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am J Pathol 159:809-815
15. McDole J, Johnson AJ, Pirko I (2006) The role of CD8+ T-cells in lesion formation and axonal dysfunction in multiple sclerosis. Neurol Res 28:256-261
16. Chofflon M (2005) Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach? BioDrugs 19:299-308
17. Brown BA, Kantesaria PP, McDevitt LM (2007) Fingolimod: a novel immunosuppressant for multiple sclerosis. Ann Pharmacother 41:1660-1668
18. Hemmer B, Hartung HP (2007) Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Ann Neurol 62:314-326
19. Cree B (2006) Emerging monoclonal antibody therapies for multiple sclerosis. Neurologist 12:171-178
20. CAMMS223 Trial Investigators et al (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359:1786-1801
21. Zeyda M et al (2005) Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum 52:2730-2739
22. Simpson BS, Coles AJ (2007) Rationale for cytotoxic monoclonal antibodies in MS. Int MS J 14:48-56
23. Genovese MC et al (2008) Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 58:2652-2661
24. Hagenbeek A et al (2008) First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 111:5486-5495
25. Silverman GJ (2006) Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms. Arthritis Rheum 54:2356-2367
26. Liossis SN, Sfikakis PP (2008) Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin Immunol 127:280-285
27. Hawker K (2008) B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data. Curr Opin Neurol 21 [Suppl 1]:19-25
28. Zouali MB (2008) Lymphocytes-chief players and therapeutic targets in autoimmune diseases. Front Biosci 13:4852-4861
29. Svensson L et al (2002) A comparative analysis of B cell-mediated myelin oligodendrocyte glycoprotein-experimental autoimmune encephalomyelitis pathogenesis in B cell-deficient mice reveals an effect on demyelination. Eur J Immunol 32:1939-1946
30. Owens GP, Bennett JL, Gilden DH, Burgoon MP (2006) The B cell response in multiple sclerosis. Neurol Res 28:236-244
31. Cepok S et al (2005) Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 128:1667-1676
32. Gilden DH et al (2001) Molecular immunologic strategies to identify antigens and B-cell responses unique to multiple sclerosis. Arch Neurol 58:43-48
33. Qin Y et al (2003) Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis. Lab Invest 83:1081-1088
34. Archelos JJ, Storch MK, Hartung HP (2000) The role of B cells and autoantibodies in multiple sclerosis. Ann Neurol 47:694-706
35. Franciotta D, Salvetti M, Lolli F et al (2008) B cells and multiple sclerosis. Lancet Neurol 7:852-858
36. Villar LM et al (2005) Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 115:187-194
37. Perini P, Ranzato F, Calabrese M et al (2006) Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis. J Neurol Neurosurg Psychiatry 77:953-955
38. Prineas JW, Graham JS (1981) Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin breakdown. Ann Neurol 10:149-158
39. Scolding NJ et al (1989) Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature 339:620-622
40. Serafini B, Rosicarelli B, Magliozzi R et al (2004) Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 14:164-174
41. Magliozzi R et al (2007) Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130:1089-1104
42. MacKay F, Tangye SG (2004) The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers. Curr Opin Pharmacol 4:347-354
43. Dillon SR, Gross JA, Ansell SM, Novak AJ (2006) An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 5:235-246
44. Krumbholz M et al (2005) BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 201:195-200
45. Thangarajh M, Masterman T, Hillert J et al (2007) A proliferation- inducing ligand (APRIL) is expressed by astrocytes and is increased in multiple sclerosis. Scand J Immunol 65:92-98
46. Thangarajh M, Gomes A, Masterman T et al (2004) Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis. J Neuroimmunol 152:183-190
47. Thangarajh M et al (2005) Increased levels of APRIL (a proliferation-inducing ligand) mRNA in multiple sclerosis. J Neuroimmunol 167:210-214
48. Weinshenker BG et al (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46:878-886
49. Hauser SL et al (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676-688
50. Keegan M et al (2005) Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366:579-582
51. Zettl UK et al (2006) Lesion pathology predicts response to plasma exchange in secondary progressive MS. Neurology 67:1515-1516
52. St-ve O et al (2005) Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol 62:1620-1623
53. Stüve O et al (2009) Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis. Arch Neurol 66:259-261
54. Kerschensteiner M et al (1999) Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 189:865-870
55. Gross JA et al (2000) TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404:995-999
56. Schneider P et al (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189:1747-1756
57. Marsters SA et al (2000) Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 10:785-788
58. Roschke V et al (2002) BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 169:4314-4321
59. Yan M et al (2001) Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol 2:638-643
60. Seshasayee D et al (2003) Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 18:279-288
61. Castigli E et al (2005) TACI and BAFF-R mediate isotype switching in B cells. J Exp Med 201:35-39
62. Castigli E et al (2005) TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 37:829-834
63. Hsu BL, Harless SM, Lindsley RC et al (2002) Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol 168:5993-5996
64. Thompson JS et al (2001) BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293:2108-2111
65. Dillon SR et al (2008) BLyS/APRIL heterotrimers activate human B cells, are elevated in SLE and RA patient sera, and are neutralized by atacicept (abstr 760). Arthritis Rheum 58:A17-A3278
66. Benson MJ et al (2008) Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 180:3655-3659
67. Gross JA et al (2001) TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity 15:289-302
68. Munafo A, Priestley A, Nestorov I et al (2007) Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur J Clin Pharmacol 63:647-656
69. Dall-Era M et al (2007) Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 56:4142-4150
70. Tak PP et al (2008) Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 58:61-72
71. Heffernan J et al (2008) The evaluation of atacicept on protective immunity in the mouse streptococcal host resistance model (abstr 1934). Toxicol Sci 102:398
72. MacKay F et al (1999) Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190:1697-1710
73. Do RK et al (2000) Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 192:953-964
74. Varfolomeev E et al (2004) APRIL-deficient mice have normal immune system development. Mol Cell Biol 24:997-1006
75. Carbonatto M et al (2008) Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept. Toxicol Sci 105:200-210
76. Nestorov I, Munafo A, Papasouliotis O, Visich J (2008) Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis. J Clin Pharmacol 48:406-417
77. Anolik J, Sanz IB (2004) B cells in human and murine systemic lupus erythematosus. Curr Opin Rheumatol 16:505-512
78. Martinez-Gamboa L, Brezinschek HP, Burmester GR, Dorner T (2006) Immunopathologic role of B lymphocytes in rheumatoid arthritis: rationale of B cell-directed therapy. Autoimmun Rev 5:437-442
79. Kalled SL (2005) The role of BAFF in immune function and implications for autoimmunity. Immunol Rev 204:43-54
80. Huntington ND et al (2006) A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses. Int Immunol 18:1473-1485
81. Lewis K et al (2008) Atacicept inhibits disease in multiple forms of experimental autoimmune encephalomyelitis. Mult Scler 14 [Suppl 1]:78(P168)
82. Plitz T et al (2008) Design of a four-arm, randomized, placebo-controlled phase II study of weeks of atacicept monotherapy in relapsing multiple sclerosis. Mult Scler 14 [Suppl 1]:173(P493)
83. Sergott RC et al (2008) Design of an exploratory, two-arm, randomized, placebo-controlled Phase II study of 36 weeks of atacicept treatment in patients with optic neuritis as clinically isolated syndrome. Mult Scler 14 [Suppl 1]:177(P508)
84. Fisher JB et al (2006) Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 113:324-332
85. Gordon-Lipkin E et al (2007) Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology 69:1603-1609
86. Frohman E et al (2006) Optical coherence tomography in multiple sclerosis. Lancet Neurol 5:853-863